New Products GTM Lead

A decade of increasing access to life saving treatments: Viz.ai celebrates 10 years, 2,000 hospitals, and 230 million patients. From the first stroke algorithm to the leading enterprise clinical AI platform, Viz.ai enters its second decade, backed by 125+ peer-reviewed publications demonstrating better patient outcomes. SAN FRANCISCO - July 28, 2026 - Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today celebrates its 10th anniversary, marking a decade of transforming how healthcare teams deliver care for patients. The company launched in 2016 to solve a key problem: variability in healthcare means that many patients fail to get guideline based care, even in life threatening diseases like stroke. Since achieving the first FDA clearance for an AI platform and increasing treatment rates and reducing disability in stroke,[1] Viz.ai has expanded across multiple diseases, and is now embedded in 2,000 hospitals serving an estimated 230 million patients with more than 50 AI care pathways spanning neurology, radiology, cardiology, oncology, pulmonology, and other disease areas. "We've spent ten years building an enterprise-grade healthcare AI platform - an AI safety net that works consistently across hospital settings, and ensures every patient has the chance of guideline based care," said Chris Mansi, MD, CEO and co-founder, Viz.ai. Today, the Viz.ai platform helps one patient every six seconds. Peer-reviewed publications, independent analyses, and health system data show: * Clinical impact: Viz.ai has consistently driven reductions in time to diagnosis, treatment, disability, and mortality - including a 74% reduction in in-hospital mortality risk in pulmonary embolism,[2] 23% reduction in post-stroke disability,[3] and reduced diagnosis time in cardiac disease.[4,5] Viz.ai's clinical impact is backed by 125+ publications, including peer-reviewed studies in NEJM AI, JAMA Neurology, JACC, Circulation, and Stroke. * Scale and validation: The company has earned recognition across the industry: Viz.ai has been rated #1 in AI-powered clinical decision support by healthcare professionals in the Black Book Market Research survey two consecutive years, ranking first in 13 of the 18 categories. The company also holds 13 FDA clearances - including the first-ever FDA de novo clearances for AI Computer Aided Triage and ECG-based cardiovascular management software - and was the first company to receive CMS reimbursement for AI software via NTAP.[6] * Strategic Partnerships: Viz.ai's partner network includes Microsoft, Salesforce, and 14 leading life sciences companies. "When we backed Viz.ai, the bet was if you build the AI System of Action for Healthcare, the patient outcomes will follow," said Mamoon Hamid, Partner at Kleiner Perkins. "A decade later, that's exactly what happened. Viz.ai is now helping one patient every six seconds." As Viz.ai enters its second decade, the platform has expanded from real-time detection and care coordination into agentic clinical intelligence at the point of care. Viz ingests multi-modal data, including imaging and EHR clinical history, and surfaces what matters, helping care teams identify high-risk patients earlier, coordinate specialists faster, and deliver guideline-aligned care consistently. Health systems can also build and deploy their own AI care pathways through Viz Agent Studio, which uses natural language on top of the Viz infrastructure trusted across 2,000 hospitals. "UC San Diego Health was among the first comprehensive stroke centers to implement and rigorously evaluate Viz.ai, and we've published our findings in peer-reviewed literature - demonstrating meaningful, sustained improvements in patient care," said Alexander Khalessi, MD, Professor and Chair of Neurosurgery and Chief Innovation Officer at UC San Diego Health. "Over the past decade, adjacent use cases in cardiology and other specialties demonstrate the promise of AI models to improve diagnostic reliability and streamline processes of care. Clinical thought leadership means never missing a decisive moment for our patients." "The problem healthcare has never solved at scale is consistency. Patients with the same condition, even at the same institution, get meaningfully different care depending on who's on shift, which specialist is available, and how the handoff happened," said Dr. Anthony Mazzarelli, Co-President and CEO, Cooper University Health Care. "What Viz.ai has built over ten years is infrastructure that makes the right thing easier to do than the wrong thing. That's rare. And it's what actually moves outcomes." About Viz.ai. Viz.ai is the leader in building and deploying AI-powered Care Pathways and helping doctors do their work. The Viz Platform is deployed in 2,000 hospitals across the United States and trusted by many of the leading life sciences companies. The platform uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company to be awarded CMS reimbursement for AI and is ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information, visit Viz.ai. Media contact. References. [1] Viz LVO De Novo FDA Clearance Letter DEN170073; corroborated by Elijovich et al., J Neurointerv Surg 2022 (doi:10.1136/neurintsurg-2021-017714) [2] Shorter time to assessment and anticoagulation with decreased mortality in patients with pulmonary embolism following implementation of artificial intelligence software. Presented at: American Venous Forum (VENOUS2024); March 3-6, 2024; Tampa, FL. [3] Morey JR, Zhang X, Yaeger KA, et al. Real-world experience with artificial intelligence-based triage in transferred large vessel occlusion stroke patients. Cerebrovasc Dis. 2021;50(4):450-455. doi:10.1159/000515320 [4] Naidu SS, Sutton MB, Gao W, Fine JT, Xie J, Desai NR, Owens AT. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ. 2023 Jan-Dec;26(1):682-690. doi: 10.1080/13696998.2023.2208966. PMID: 37170479. [5] Love, C.J., Lampert, J., Huneycutt, D., et al. "A Multicenter, Prospective Cohort Pilot Study on the Clinical Implementation and Utilization of an AI-based ECG Tool for HCM Detection and Care Coordination." Presented at the American College of Cardiology (ACC) Conference, March 2025 [6] Viz.ai was the first AI software company to receive CMS reimbursement via New Technology Add-On Payment (NTAP)

Viz.ai, an AI-powered disease detection platform deployed in nearly 2,000 US hospitals, has announced a collaboration with Cortechs.ai to expand into neurodegenerative disease. The partnership will integrate Cortechs.ai's NeuroQuant and NeuroQuant MS neuroimaging tools into Viz.ai's platform, initially focusing on multiple sclerosis. The collaboration combines quantitative MRI analysis with Viz.ai's care coordination workflow, enabling clinicians to identify and manage MS patients at scale. Dr Tim Showalter, chief medical officer at Viz.ai, said the partnership extends the company's mission into an area with "profound unmet need", where earlier patient identification can change treatment trajectories. Viz.ai plans to announce additional partnerships and products focused on neurodegenerative diseases in the near future.